


COVID-19

RACCOMANDAZIONI NEL TRATTAMENTO DEL PAZIENTE COVID-19





Trattamento Terapeutico nel paziente COVID-19

Therapeutics and COVID-19


LIVING GUIDELINE
17 December 2020



Questo breve riassunto per immagini è basato sull'ultima versione del documento WHO Therapeutics and COVID-19: living guideline aggiornato al 17 Dicembre 2020.



<https://apps.who.int/iris/bitstream/handle/10665/337876/WHO-2019-nCoV-therapeutics-2020.1-eng.pdf>



Il ruolo dell'intervento farmacologico nel trattamento al paziente con COVID-19

Nuove Raccomandazioni : L'ultima versione della linea guida WHO raccomanda fortemente di NON utilizzare idrossiclorochina a lopinavir – ritonavir nei pazienti con COVID-19 indipendentemente dalla severità del quadro clinico. Queste raccomandazioni si attengono alla pubblicazione dei risultati ottenuti dalla ricerca WHO SOLIDARITY trial.

Raccomandazioni: In questa linea guida si continua a raccomandare l'utilizzo di corticosteroidi e remdesivir senza apportare nessuna modifica rispetto alla versione precedente :

- A. Corticosteroidi sistemici fortemente raccomandati in pazienti con quadro clinico COVID-19 severo e critico
- B. Raccomandazione condizionata contro l'uso dei corticosteroidi sistemici nei pazienti con quadro clinico moderato o non severo
- C. Raccomandazione condizionata contro l'utilizzo di remdesivir in pazienti ospedalizzati per COVID-19


Population

This recommendation applies only to people with these characteristics:



Interventions

	Disease severity		
	Non-severe	Severe	Critical
	Absence of signs of severe or critical disease	SpO ₂ <90% on room air Respiratory rate >30 in adults Raised respiratory rate in children Signs of severe respiratory distress	Requires life sustaining treatment Acute respiratory distress syndrome Sepsis Septic shock
Hydroxychloroquine	Recommendation against (strong)		
Lopinavir-ritonavir	Recommendation against (strong)		
Remdesivir	Recommendation against (weak)		
Corticosteroids	Recommendation against (weak)	Recommendation in favour (strong)	




I dati che hanno portato a sconsigliare fortemente l'uso di idrossiclorochina e lopinavir – ritonavir in pazienti con Covid-19 provengono da un'analisi condotta su 30 studi a cui hanno partecipato 10921 pazienti trattati con idrossiclorochina e 7 studi effettuati su 7429 pazienti trattati con lopinavir – ritonavir. Gli studi per entrambi i farmaci includevano pazienti ospedalizzati e pazienti ambulatoriali.

I dati raccolti non hanno dimostrato alcuna riduzione sulla mortalità o necessità di ventilazione meccanica e hanno valutato come bassa la certezza di prove danni provocati dall'uso dei due farmaci inclusi effetti collaterali come diarrea e nausea.

Il gruppo di ricerca ha valutato inoltre che fattori contestuali come risorse, fattibilità, accettabilità ed equità per i paesi e i sistemi sanitari non hanno alterato le raccomandazioni espresse dai dati della ricerca.

Hydroxychloroquine

Suggested regimen



Recommendation 1



Evidence profile

Favours usual supportive care


No important difference ⁱ

Favours hydroxychloroquine


	Events per 1000 people		Evidence quality
Mortality	106	No important difference	116 ★★★★★ Moderate
Mechanical ventilation	105	No important difference	123 ★★★★★ Moderate
Viral clearance at 7 days	483	No important difference	502 ★★★★★ Very low
Admission to hospital	47	No important difference	19 ★★★★★ Very low
Cardiac toxicity	46	No important difference	56 ★★★★★ Very low
Diarrhoea	149	106 fewer	255 ★★★★★ Low
Nausea/vomiting	99	62 fewer	161 ★★★★★ Low
Delirium	62	No important difference	95 ★★★★★ Very low
	Mean days		Evidence quality
Time to clinical improvement	11.0	No important difference	9.0 ★★★★★ Very low
Duration of hospitalisation	12.8	No important difference	12.9 ★★★★★ Low
Time to viral clearance	9.7	No important difference	10.6 ★★★★★ Very low
Adverse events (discontinuation)	2	No important difference	0 ★★★★★ Very low

Lopinavir-ritonavir

Suggested regimen



Recommendation 1



Evidence profile

Favours usual supportive care


No important difference ⁱ

Favours lopinavir-ritonavir


	Events per 1000 people		Evidence quality	
Mortality	106	No important difference	106	★★★★ Moderate
Mechanical ventilation	105	No important difference	120	★★★★ Moderate
Viral clearance at 7 days	483	No important difference	246	★★★★ Very low
Acute kidney injury	45	No important difference	25	★★★★ Very low
Diarrhoea	67	168 fewer	235	★★★★ Low
Nausea or vomiting	17	160 fewer	177	★★★★ Low
	Mean days		Evidence quality	
Time to clinical improvement	11.0	No important difference	10.0	★★★★ Very low
Duration of hospitalisation	12.8	No important difference	12.5	★★★★ Low

Remdesivir

Suggested regimen



Recommendation 1



Evidence profile



	Events per 1000 people		Evidence quality
Mortality	106	No important difference	96 ★★★★★ Low
Mechanical ventilation	105	No important difference	95 ★★★★★ Low
Serious adverse events	15	No important difference	15 ★★★★★ Low
Viral clearance at 7 days	483	No important difference	498 ★★★★★ Very low
Acute kidney injury	56	No important difference	48 ★★★★★ Low
Delirium	16	No important difference	19 ★★★★★ Very low
	Mean days		Evidence quality
Time to clinical improvement	11.0	No important difference	9.0 ★★★★★ Low
Hospitalisation duration	12.8	No important difference	12.3 ★★★★★ Low
Mechanical ventilation duration	14.7	No important difference	13.4 ★★★★★ Low

Corticosteroids

Corticosteroids Suggested regimen

Dexamethasone

6 mg

Oral or intravenous

 Daily for
7-10 days

Acceptable alternative regimens

Hydrocortisone

50 mg

Intravenous

 Every 8 hours
for 7-10 days

Methylprednisolone

10 mg

Intravenous

 Every 6 hours
for 7-10 days

Prednisone

40 mg

Oral

 Daily for
7-10 days

Recommendation 1

Usual supportive care

Strong

or

Weak

Corticosteroids

Weak

or

Strong

Patients with severe and critical covid-19

“

We recommend corticosteroids

”

Evidence profile					
	Favours usual supportive care	No important difference	Favours corticosteroids		
	Events per 1000 people				Evidence quality
Mortality with critical illness	415	87 fewer	328	★★★★★	Moderate
Mortality with severe illness	334	67 fewer	267	★★★★★	Moderate
Gastrointestinal bleeding	48	No important difference	51	★★★★★	Low
Superinfections	186	No important difference	188	★★★★★	Low
Hyperglycaemia	286	46 fewer	332	★★★★★	Moderate
Neuromuscular weakness	69	No important difference	75	★★★★★	Low
Neuropsychiatric effects	35	No important difference	28	★★★★★	Low

Recommendation 2

